Preclinical
A summary of daily Biopharma industry news. Please check out stories that are trending on March 19, 2020.
As the number of diagnosed cases of COVID-19 continue to increase across the globe and more and more governments are urging citizens to self-quarantine, the pharmaceutical and life sciences industry continues to work toward the development of a vaccine and therapies for the respiratory infection that was declared a pandemic by the World Health Organization last week. Here’s a biopharma industry overview as of late March 16.
Each year, BioSpace evaluates biotech startups for the last year and applies an algorithm that includes funding, collaboration, the state of their pipeline and editorial awards for innovation.
Marinomed Biotech AG, a globally active biopharmaceutical company with headquarters in Vienna, and the renowned University of Utah have published scientific investigations that provide initial evidence for further significant benefits of the innovative Marinosolv® platform in the field of corneal eye diseases.
CYNBIOME receives funding under Investments for the Future Program (PiA), supplemented by €3M ($3.3M) of Cynbiose’s own funds
Ben Zeskind, chief executive officer of Immuneering, spoke with BioSpace following the annual J.P. Morgan Healthcare conference in San Francisco.
What’s New at the J.P. Morgan Life Healthcare Conference?
With a new year underway, the U.S. Food and Drug Administration is doing some house-cleaning of sorts.
MR Solutions is continuing to expand its support network as its base of preclinical liquid helium free multimodality MRI systems become the norm in research laboratories across the world.
It can be a bit difficult to predict exactly what the big stories out of the JP Morgan Healthcare Conference are going to be. There’s no telling if some surprise deal will take the air out of the room, but here’s a look at some of the top presentations.
PRESS RELEASES